Saitama Medical University and Yakult Honsha Co.,ltd. applied the patent[the susceptibility testing method to determine antineoplastic drug irinotecan and usage] by PCT Patent Cooperation Treaty(PCT/JP2010/001772) application date at 12 May 2010, priority date at 13 May 2009.


Dr. Masahiko Nishiyama(Saitama medical University) is developed the method to judge susceptibility testing of irinotecan to determine expression levels of specific gene, this is a result of collaborate research, it’s one of the active coordination with university and private enterprises Yakult Honsha Co.,ltd.

This method gives cancer patients appropriate treatment to predict the effect of irinotecan before and after administration.